JAK1-deficient or mutant cell lines show greater tumorigenicity, which has been reported in patients with hepatocellular carcinoma, acute lymphoblastic leukemia, lung cancer, and gastric cancer [14–16]. Here, JAK1 is linked to lung carcinoma.